Lupin Pharmaceuticals Inc (LPI), wholly-owned subsidiary of Lupin Ltd, has entered into an agreement with Chester Valley Pharmaceuticals in the United States to promote Atopiclair non-steroidal cream to paediatricians. Atopiclair non-steroidal cream is the first prescription medical device authorised by the US FDA to relieve symptoms of atopic dermatitis and allergic contact dermatitis.

Under the terms of the agreement, LPI's paediatric sales force will promote Atopiclair non-steroidal cream to paediatric prescribers. Chester Valley Pharmaceuticals will continue to promote Atopiclair non-steroidal cream to dermatologists and other prescribers, claims a company release.

LPI president, Vinita Gupta said, "We are pleased to enter into this relationship with Chester Valley Pharmaceuticals. We believe that LPI's paediatric sales force will expand the usage of this new product for atopic dermatitis and allergic contact dermatitis among paediatricians."